Tirellizumab+Anlotinib VS Anlotinib for MSS-type CRC

NALIRIFOX Plus Targeted Therapy Versus FOLFOX Plus Targeted Therapy as First-line Treatment for Metastatic Colorectal Cancer

NCT07309289 ·Status: RECRUITING ·Phase: PHASE3

A Real-world Study of Chidamide in Combination with PD-1/PD-L1 Antibodies and Anti-angiogenic Agents in Advanced MSS Colorectal Cancer

NCT06682247 ·Status: NOT_YET_RECRUITING

Phase II RCT of LCRT vs SCRT + CAPOX/PD-1i/COX-2i in MSS Locally Advanced Rectal Cancer

NCT07154316 ·Status: RECRUITING ·Phase: PHASE2

PCSK9 Inhibitor and PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy for pMMR/MSS Locally Advanced Rectal Cancer

NCT06933251 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Neoadjuvant Chemoradiotherapy Plus Sintilimab for MSS, Locally Advanced Rectal Cancer-

NCT06895577 ·Status: WITHDRAWN ·Phase: PHASE2

Efficacy of Combination Immunotherapy in Patients With Metastatic Colorectal Cancer

NCT05414461 ·Status: COMPLETED ·Phase: PHASE2

Neoantigen-based Peptide Vaccine and Conventional Second-line Therapy for CRC Progressed After First-line Treatment

NCT06751914 ·Status: RECRUITING ·Phase: NA

mFOLFOX6+Bevacizumab+PD-1 Monoclonal Antibody in Local Advanced MSS CRC

NCT04895137 ·Status: COMPLETED ·Phase: PHASE2

Real-World Study of Chidamide Combined With PD-(L)1 Inhibitors and Anti-Angiogenic Therapy for Advanced MSS-Type Colorectal Cancer

NCT06858956 ·Status: NOT_YET_RECRUITING

Effect of Gut Microbiota and Its Metabolites on the Efficacy of Immunotherapy in Metastatic Colorectal Cancer

NCT06714903 ·Status: RECRUITING

Radiotherapy Combined With Tislelizumab and Irinotecan in MSS/pMMR Recurrence and Metastatic Colorectal Cancer

NCT05160727 ·Status: UNKNOWN ·Phase: PHASE2

"Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer"

NCT06829355 ·Status: RECRUITING ·Phase: PHASE2

First-line Treatment of MCapOX + Cetuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided MCRC: a Multicenter, Randomized, Controlled, Phase III Study

NCT06616259 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3

A Combination Therapy Including Anti-PD-1 Immunotherapy in MSS Rectal Cancer With Resectable Distal Metastasis

NCT05359393 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

The Combination of Immunotherapy and Stereotactic Ablative Radiotherapy in MSS Oligometastatic Colorectal Cancer

NCT04535024 ·Status: UNKNOWN ·Phase: PHASE2

Neoadjuvant Therapy for Locally Advanced Rectal Cancer

NCT06853769 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1

A Study of Cetuximabβ Combined With Envolimab and mFOLFOX6 in Subjects With Advanced Colorectal Cancer

NCT07000305 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Nodes-sparing Short-course Radiation Combined With CAPOX and Tislelizumab for MSS Middle and Low Rectal Cancer

NCT05972655 ·Status: RECRUITING ·Phase: PHASE2

The Clinical Outcome and the Exploration of Related Biomarkers of Target Therapy in Metastasis Colorectal Cancer

NCT02523495 ·Status: UNKNOWN

FMT+Immunotherapy+Chemotherapy As First-line Treatment for Driver-gene Negative Advanced NSCLC

NCT06403111 ·Status: RECRUITING ·Phase: PHASE2

Chemotherapy Sequential Tislelizumab After Radical Resection in Patients With dMMR/MSI-H or POLE/POLD1 Mutations

NCT06118658 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Cadonilimab Combined With Regorafenib as A Third-line Treatment in Patients With MSS CRLM

NCT06455254 ·Status: RECRUITING ·Phase: PHASE2

Evaluation of Efficacy and Safety of PD-1 Monoclonal Antibody in Combination With rhG-CSF, IL-2, and CapeOX in Initially Resectable Synchronous Colorectal Liver Metastases

NCT06504901 ·Status: NOT_YET_RECRUITING

Efficacy and Safety Study of Combination of CPGJ602 and Chemotherapy, in First Line, With Wild KRAS/NRAS/BRAF in Metastatic Colorectal Cancer

NCT04466254 ·Status: UNKNOWN ·Phase: PHASE2

Efficacy and Tolerance of Maintenance Therapy in Patients With Incurable Advanced Colorectal Cancer

NCT02071069 ·Status: UNKNOWN ·Phase: PHASE2